Assay

Financial-condition grades for SEC filers

Company Report · as of Oct 9, 2026


HomeCompaniesSectorsCalendarLast night

CEL SCI Corp.CVM · healthcare
GradeNonecomputable_factors_below_threshold: 6 of 14 inputs computable; 7 are required
Reliability0.83 AUCfailure model, filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate1.07% a yearItem 1.03 bankruptcies, same asset band, 2012 to 2025
Size band$12.5M to $120M assetstotal assets $28.2M[1]
Standard universeoutsiderevenue above $1M and assets above $10M[1-2]
Warningsdilution, late filer, thin datanot computable: short runway, distress, fortress balance sheet
Inputs computable6 of 14
Graded fromfilings received through Dec 29, 2025284 days before the rescan; every figure keyed to the SEC receipt date
Last close$2.032026-10-08; market equity $35.7M; iex feed
Price used in gradeNone
Share price, twelve months to the rescansplit-adjusted close; a lollipop at every rescan carries the letter held then; baseline ticks are SEC receipt dates of the inputs; ranges and dragging scroll the full history
$5$10NovDecJanFebMarAprMayJunJulAugSepOct$1.95
ABCDE20132014201520162017201820192020202120222023202420252026

Percentile at every rescan on file, Jan 21, 2012 to Oct 9, 2026; stronger toward the top. Hover for the date.

Open this report as it stood on

Letter setLetterPercentileBand
Jan 21, 2012nonen/aQ2
Jan 21, 2014nonen/aQ1
Jan 21, 2015nonen/aQ2
Dec 21, 2016nonen/aQ1
Dec 21, 2017nonen/aQ2

Each date opens the report as it stood on that rescan.

Business, in the company's words. Opening of Item 1 of the 10-K received Dec 29, 2025; the document on sec.gov.

CEL-SCI Corporation is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body’s natural defense system. CEL-SCI is currently focused on the development of the following product candidates and technologies with an emphasis on Multikine: Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; and L.E.A.P.S. (Ligand Epitope Antigen Presentation System) technology, or LEAPS, with several product candidates under development for the potential treatment of rheumatoid arthritis.

Warnings [top]

Dilution. split-adjusted year-over-year share growth is 240.3%[3-4]
Late filer. found 1 NT 10-K/Q filings in the last eight quarters
Thin data. 6 of 14 grade factors are computable; minimum is 7

7 checks ran; none of them enters the letter. The checks are listed on the warnings screen.

The Fourteen Inputs [top]

Lower percentile is stronger. Source numbers open the SEC filing; a range that spans filings opens the sources table.

InputPercentile, 0 to 100ValueSourcePeer medianPercentilePeersPeriod end
Profitability, sleeve percentile 14.4
Gross profitabilitynot computable32.2%
one or more required annual facts are missing
Return on invested capitalnot computable9.3%
one or more required annual facts are missing
Accruals ratio(30.1%)[1,5-7](6.6%)14.48112025-09-30
Gross margin stability, five yearsnot computable2.8 pts
five annual gross margins are required; found 0
Solvency, sleeve percentile 80.0
Twelve-month failure probabilitynot computable0.07%
latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime(65.50)[1,8-13](0.31)91.17562025-09-30
Net debt to EBITDAnot computable1.82x
required facts have no common fiscal period end
Interest coverage(38.23x)[11,14](4.51x)81.2812025-09-30
Current ratio2.26x[8-9]2.96x67.58392025-09-30
Growth and financing, sleeve percentile 85.3
Revenue growth, three-year compoundnot computable10.0%
four annual observations are required; found 3
Free cash flow growth, three-year compoundnot computable10.9%
current FCF must be positive and base FCF must exceed $100,000
Reinvestment ratenot computable37.1%
one or more required annual facts are missing
Asset growth, three years(17.7%)[1,7,15-16]2.1%79.87042025-09-30
Net share issuance, one year240.3%[3-4]2.5%90.86342025-12-19

Gross profitability. Revenue less cost of goods sold, over total assets.

Accruals ratio. Net income less operating cash flow, over average assets; lower is stronger.

Gross margin stability, five years. Standard deviation of gross margin; lower is stronger.

Twelve-month failure probability. CHS model; lower is stronger.

Net debt to EBITDA. Lower is stronger.

Net share issuance, one year. Split-adjusted; lower is stronger.

Among 371 Peers [top]

What the Price Implies [top]

Market measures at the 2026-10-08 close. None enters the grade. Percentile among graded peers with the same measure.

MeasureValuePeer medianPercentileReading
Twelve-month price change, skipping the latest month(82.4%)8.0%4hotter than 4 of 100 peers
Distance from 52-week high(80.7%)(31.4%)8closer to its high than 8 of 100 peers
EBIT to enterprise value(71.2%)(1.5%)10pricier than 90 of 100 peers
Free cash flow yield(50.0%)(1.0%)12pricier than 88 of 100 peers
Book value to price0.320.2853pricier than 47 of 100 peers
Sales to price0.010.316pricier than 94 of 100 peers
Composite equity issuance, five years258.6%20.3%94more equity-funded than 94 of 100 peers
Relative strength against the sector, log excess return(1.95)(0.14)4ahead of 4 of 100 peers

Inputs: market equity $34.3M; EBIT -$24.8M; free cash flow -$17.2M; book equity $11.0M; sales $264,033; debt $5.7M; cash $5.1M[17].

Diagnostics [top]

Diagnostics do not feed the grade.

Piotroski F-score: None of 9, period end 2025-09-30
Return on assets above zero(94.1%)✗ fail[5,7]
Operating cash flow above zero-$17.1M✗ fail[6]
Return on assets improved(6.0 pts)✗ fail[5,7,15,18]
Operating cash flow exceeds net income$8.3M✓ pass[5-6]
Long-term leverage felln/a[1,7,15,19]
Current ratio improved94.8 pts✓ pass[8-9,20-21]
No new shares issued240.3%✗ fail[3-4]
Gross margin improvedn/a
Asset turnover improvedn/a[7,15]
Cash, filings, liquidity
Cash and equivalentsn/a
Operating cash flow, four quartersn/a[6,22-25]
Months of runwaynot finite
cash is missing at the end of the latest cash-flow quarter
Late filings, two years1
NT 10-K or NT 10-Q
Days since last periodic filing56
10-Q received Aug 14, 2026
Median daily dollar volume$226,274
63 sessions
Days since newest grade input284

Downloads [top]

Sources [top]

Every citation on this page. Filing opens the SEC index page for that submission; viewer opens the SEC interactive data for the same filing; series opens the SEC XBRL API record for that tag and company.

#ConceptXBRL tagValuePeriod endReceivedFormLinks
1assetsus-gaap:Assets$28.2M2025-09-302025-12-2910-Kfiling · viewer · series
2revenueus-gaap:Revenues$264,0332014-09-302014-12-2310-Kfiling · viewer · series
3shares outstandingdei:EntityCommonStockSharesOutstanding8,408,7462025-12-192025-12-2910-Kfiling · viewer · series
4shares outstandingdei:EntityCommonStockSharesOutstanding74,107,0412025-01-062025-01-1310-Kfiling · viewer · series
5net incomeus-gaap:NetIncomeLoss-$25.4M2025-09-302025-12-2910-Kfiling · viewer · series
6operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$17.1M2025-09-302025-12-2910-Kfiling · viewer · series
7assetsus-gaap:Assets$27.0M2024-09-302025-12-2910-Kfiling · viewer · series
8current assetsus-gaap:AssetsCurrent$11.6M2025-09-302025-12-2910-Kfiling · viewer · series
9current liabilitiesus-gaap:LiabilitiesCurrent$5.1M2025-09-302025-12-2910-Kfiling · viewer · series
10retained earningsus-gaap:RetainedEarningsAccumulatedDeficit-$539.4M2025-09-302025-12-2910-Kfiling · viewer · series
11operating incomeus-gaap:OperatingIncomeLoss-$24.8M2025-09-302025-12-2910-Kfiling · viewer · series
12book equityus-gaap:StockholdersEquity$16.0M2025-09-302025-12-2910-Kfiling · viewer · series
13liabilitiesus-gaap:Liabilities$12.2M2025-09-302025-12-2910-Kfiling · viewer · series
14interest expenseus-gaap:InterestExpense$649,0002025-09-302025-12-2910-Kfiling · viewer · series
15assetsus-gaap:Assets$30.5M2023-09-302025-01-1310-Kfiling · viewer · series
16assetsus-gaap:Assets$50.5M2022-09-302023-12-2110-Kfiling · viewer · series
17shares outstandingdei:EntityCommonStockSharesOutstanding17,588,9872026-08-102026-08-1410-Qfiling · viewer · series
18net incomeus-gaap:NetIncomeLoss-$26.9M2024-09-302025-12-2910-Kfiling · viewer · series
19long term debtus-gaap:LongTermDebtAndCapitalLeaseObligations$5.7M2025-09-302025-12-2910-Kfiling · viewer · series
20current assetsus-gaap:AssetsCurrent$6.1M2024-09-302025-12-2910-Kfiling · viewer · series
21current liabilitiesus-gaap:LiabilitiesCurrent$4.6M2024-09-302025-12-2910-Kfiling · viewer · series
22operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$12.1M2026-06-302026-08-1410-Qfiling · viewer · series
23operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$8.0M2026-03-312026-05-1510-Qfiling · viewer · series
24operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$4.0M2025-12-312026-02-1710-Qfiling · viewer · series
25operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$12.4M2025-06-302026-08-1410-Qfiling · viewer · series

Limitations [top]

Peer group. Sector assignment from four-digit SIC codes, hand-tuned and published. The grade under three alternative peer policies is tabled above.

Size. Within a sector the letter tracks size. Among graded filers in the smallest asset band, 72% grade E and 0% grade A; in the largest, 13% grade E and 21% grade A. Universe as of Oct 9, 2026.

Failure model. filings 2012-01-01 to 2019-12-31 fit, filings 2020-01-01 to 2025-12-31 test; status post hoc pending confirmation. pre-registered on 2026 filings once their 12-month outcome windows close; supported if the paired per-quintile gain over the pooled model has a lower bound above 0.05.

Input validity. Revenue or total assets at or below $100,000 sets the degenerate-inputs flag. An input whose denominator is at or below $100,000 is left not computable rather than ranked.

Returns. No input on this page has a post-2015 confidence interval on returns that excludes zero. The grade ranks reported financial condition and is not a return forecast.